Overview

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

Status:
Completed

Trial end date:
2012-07-16

Target enrollment:

Participant gender:

Summary

A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Spironolactone